XML 94 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Income taxes (Tables)
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2022
Major components of tax expense (income) [abstract]    
Disclosure of income tax recovery [Table Text Block]  
                Nine months  
    Year end ended     Year ended     ended  
    September 30,     September 30,     September 30,  
    2022     2021     2020  
Current income tax recovery (expense): $ -   $ -   $ -  
Deferred income tax (recovery) expense:   (49,442 )   -     -  
  $ (49,442 ) $ -   $ -  
Disclosure of reconciliation of effective income tax rate [Table Text Block]
    Nine months
ended
September 30,
2020		     Twelve months
ended
December 31,
2019		  
    (Adjusted  - see
Note 8)		      (Restated - see
Note 25) 		  
Loss before income taxes $ (3,536,778 )   (1,147,280 )
Expected statutory tax rate   26.5%     26.5%  
Expected tax recovery resulting from loss   (937,246 )   (304,029 )
             
Increase (reduction) in income taxes resulting from:            
  Non-deductible expenses   275,273     28,115  
  Unrecognized temporary differences   661,973     275,914  
  $ -   $ -  
                Nine months  
    Year ended     Year ended     ended  
    September 30,     September 30,     September 30,  
    2022     2021     2020  
Loss before income taxes $ (10,569,732 ) $ (9,315,372 ) $ (3,536,778 )
Expected statutory tax rate   26.5%     26.5%     26.5%  
Expected tax recovery resulting from loss   (2,800,979 )   (2,468,574 )   (937,246 )
                   
Increase (reduction) in income taxes resulting from:                  
  Non-deductible expenses   563,842     654,956     275,273  
  Foreign operations subject to different tax rates   5,329     3,593     -  
  Unrecognized temporary differences   2,182,366     1,826,279     661,973  
  Prior year differences   -     (16,254 )   -  
  $ (49,442 ) $ -   $ -  
Disclosure of research and development expense [Table Text Block]  
    Year ended     Year ended     Year ended  
    September 30,     September 30,     September 30,  
    2022     2021     2020  
                   
R&D expenses $ 2,064,493   $ 2,369,145   $ 944,909  
Less:                  
Investment tax credits   -     (231,007 )   (127,325 )
R&D expenses, net   2,064,493     2,138,138     817,584  
Disclosure of deferred taxes [Table Text Block]
    Balance at
December 31,
2019		     Recognized in
profit or loss		     Recognized in
equity		     Balance at
September 30,
2020		  
                         
Deferred tax assets (liabilities):                        
  Net operating loss carryforwards $ -   $ 48,045   $ -   $ 48,045  
  Intangible assets   -     (48,045 )         (48,045 )
  $ -   $ -   $ -   $ -  
    Balance at     Arising on a           Balance at  
    September 30,     business     Recognized in     September 30,  
    2021     combination     profit or loss     2022  
Deferred tax assets (liabilities):                        
Net operating loss carryforwards   -     -     26,459     26,459  
Intangibles and development costs   -     (49,442 )   22,983     (26,459 )
    -     (49,442 )   49,442     -  
    Balance at                 Balance at  
    September 30,     Recognized in     Recognized in     September 30,  
    2020     profit or loss     Equity     2021  
                         
Deferred tax assets (liabilities):                        
  Net operating loss carryforwards   48,045     (48,045 )   -     -  
  Impairment provision   (48,045 )   48,045     -     -  
    -     -     -     -  
                         
    Balance at                 Balance at  
    December 31,     Recognized in     Recognized in     September 30,  
    2019     profit or loss     Equity     2020  
                         
Deferred tax assets (liabilities):                        
  Net operating loss carryforwards   -     48,045     -     48,045  
  Impairment provision   -     (48,045 )   -     (48,045 )
    -     -     -     -  
Disclosure of unrecognized net deferred tax assets [Table Text Block]
    Balance at     Balance at   
    September 30,     December 31,   
    2020     2019  
             
Net operating loss carryforwards $ 4,279,494   $ 2,111,531  
Share issuance costs   1,496,239     17,281  
Scientific research and development expenditures   218,235     170,940  
Other   46,891     22,106  
  $ 6,040,859   $ 2,321,858  
    Balance at     Balance at     Balance at  
    September 30,     September 30,     September 30,  
    2022     2021     2020  
Net operating loss carryforwards   18,589,894     9,429,436     4,279,494  
Share issuance costs   1,298,783     1,810,927     1,496,239  
Intangibles and development costs   608,705     780,607     -  
Scientific research and development expenditures   1,583,058     1,789,571     218,235  
Other   46,300     104,793     46,891  
    22,126,741     13,915,334     6,040,859  
Disclosure of net operating losses [Table Text Block]
Year of expiry   Amount  
2036 $ 512,163  
2037   611,677  
2038   1,174,797  
2039   1,829,518  
2040   332,641  
  $ 4,460,796  
Year of Expiry   Amount  
       
2036 $ 512,163  
2037   744,022  
2038   1,174,797  
2039   1,732,039  
2040 and thereafter   14,526,720  
  $ 18,689,741  
Disclosure of research and development investment tax credits [Table Text Block]  
Year of Expiry   Amount  
       
2037 $ 13,361  
2038   6,742  
2039   -  
2040 and thereafter   328,480  
  $ 348,583